PHILADELPHIA—A pair of phase 3 clinical trials have yielded promising results about the potential benefits of suzetrigine, a potent and highly selective inhibitor of the voltage-gated sodium channel 1.8 (NaV1.8), in the treatment of moderate to severe acute pain. The studies found that the novel agent was as effective as a hydrocodone-based opioid regimen in both abdominoplasty and bunionectomy models, with a very favorable safety profile.
“Suzetrigine is a potent, nonopioid small